Search

A new targeted combination therapy with potential to eliminate relapsed chronic lymphocytic leukemia

Patients with chronic lymphocytic leukemia (CLL) that has recurred or isn’t responding to standard treatment need new therapies. A new combination of two targeted therapies is showing potential to eliminate CLL in these circumstances.

Read more

EHA Endorsement of ESMO Clinical Practice Guidelines for Diagnosis, Treatment, and Follow-up of Chronic Lymphocytic Leukemia

European Hematology Association (EHA) and European Society for Medical Oncology (ESMO) agreed to collaborate on the production of European Guidelines for different hematological malignancies.

Read more

EHA Statement of Solidarity with local communities in Türkiye and Syria

The European Hematology Association (EHA) is deeply concerned about the situation in southern Türkiye and northern Syria: Monday's earthquakes and aftershocks have killed thousands of people and destroyed innumerable buildings, while freezing temperatures and damaged roads are hampering rescue efforts.

Read more

Evidence and policy to ensure good clinical practice

Interview with Vinay Prasad MD MPH by Heiko Becker MD, on behalf of YoungEHA

Leaders in the field that have the potential to make a difference, that challenge the way we are doing things, who push our perspective out of our…

Read more

EHA-SWG Scientific Meeting on Integrated Cell Tracking in Oncohematology: Diagnosis, Targeted Therapy and Residual Disease

November 10-11, 2022 | Bordeaux, France

Meeting Chairs:
MC Béné, Nantes University
G Zini, Università Cattolica S.

Read more

EHA Research Conference 2025

Dates: March 17-20, 2025
Location: Málaga, Spain
Chairs: Alba Maiques, Ruud Delwel, Panagiotis Ntziachristos, Marcus Buschbeck, Mark Dawson, 
Özgen Deniz, Kimberley Stegmaier, and Nina Cabezas-Wallscheid

Registration is now open

EHA is proud to announce the third edition of the EHA Research Conference, titled "Transcriptional control and chromatin alterations in normal and abnormal hematopoiesis".…

Read more